Features of supratentorial primitive neuroectodermal tumors in young children

Authors

  • Yuriy Orlov Department of Pediatric Neurosurgery, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Andrii Shaverskyi Department of Pediatric Neurosurgery, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Andriy Svyst Department of Pediatric Neurosurgery, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Volodymyr Mykhalyuk Department of Pediatric Neurosurgery, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Vadim Zyabchenko Department of Pediatric Neurosurgery, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Tatyana Malysheva Neuropathomorphology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Oksana Chernenko Neuropathomorphology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • S. Dovzhenko Neuropathomorphology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine

DOI:

https://doi.org/10.25305/unj.55647

Keywords:

brain tumors, supratentorial primitive neuroectodermal tumors, surgery, chemotherapy, young children

Abstract

Introduction. Supratentorial primitive neuroectodermal tumors (sPNET) are highly malignant neoplasms with much more worse prognosis than at medulloblastomas. A retrospective analysis of treatment in the clinic of children under 3 years with sPNETs are given.

Materials and methods. In the period from 1998 and 2009 years, 20 children under 3 years with sPNET, there were 10 boys and 10 girls have been treated in the clinic — 4.6% of all infants with brain tumors, diagnosed for that period of time.

Results. Total tumor resection was performed in 6 (30%) patients, subtotal — in 6 (30%), partial — in 6 (30%), in 2 — biopsy was made. Postoperative lethality — 22%. In 9 (45%) observations the tumor was classified as cerebral neuroblastoma, in 1 (5%) — as cerebral ganglioneuroblastoma. Tumor cells in liquor were found in 11.8% cases, metastasis in other parts of the brain — in 15%, extraneural dissemination — in 2 patients. 11 (73.3%) underwent chemotherapy, 3 (20%) — radiation therapy. Follow-up data from 1 year to 7 years are available in 86.7% patients. The median survival was 42 months, 2- and 5-year survival — 61.5 and 15.4% respectively, recurrence rate — 20%.

Conclusions. sPNET in children are relatively rare, they are one of the most malignant brain tumors. Chemotherapy inclusion into complex treatment promotes survival prolongation. To improve results of treatment in children with sPNET further search for effective complex of combined treatment of such tumors is required, especially in young children.

References

1. Berger M, Magrassi L, Geyer R. Medulloblastoma and primitive neuroectodermal tumors. In: Kaye A, Laws E, ed. Brain Tumors. An Encyclopedic Approach. Edinburgh: Churchill Livingstone; 1995:561-574.

2. Rosemberg S, Fujiwara D. Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: a report of 1,195 cases from a single institution. Childs Nerv Syst. 2005;21(11):940-944. [CrossRef] [PubMed]

3. Li M, Bouffet E, Hawkins C, Squire J, Huang A. Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurgical FOCUS. 2005;19(5):1-17. [CrossRef] [PubMed]

4. Albright L, Wisoff J, Zeltzer P et al. Prognostic Factors in Children with Supratentorial (Nonpineal) Primitive Neuroectodermal Tumors. Pediatric Neurosurgery. 1995;22(1):1-7. [CrossRef]

5. Gurney J, Smith M, Bunin G. CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries L, Gurney M, Smith G, ed. Cancer Incidence And Survival Among Children And Adolescents: United States SEER Program 1975—1995, National Cancer Institute, SEER Program. 1st ed. Bethesda: NIH Publ.; 1999:99-4646.

6. McNeil D, Cote T, Clegg L, Rorke L. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Med Pediatr Oncol. 2002;39(3):190-194. [CrossRef] [PubMed]

7. Weil M. Influence of a Childs Sex on Medulloblastoma Outcome. JAMA. 1998;279(18):1474-1476. [CrossRef] [PubMed]

8. Fangusaro J, Finlay J, Sposto R et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatr Blood Cancer. 2008;50(2):312-318. [CrossRef] [PubMed]

9. Tarbell N, Loeffler J, Silver B et al. The change in patterns of relapse in medulloblastoma. Cancer. 1991;68(7):1600-1604. [CrossRef] [PubMed]

Published

2012-12-07

How to Cite

Orlov, Y., Shaverskyi, A., Svyst, A., Mykhalyuk, V., Zyabchenko, V., Malysheva, T., Chernenko, O., & Dovzhenko, S. (2012). Features of supratentorial primitive neuroectodermal tumors in young children. Ukrainian Neurosurgical Journal, (4), 46–49. https://doi.org/10.25305/unj.55647

Issue

Section

Original articles